Mayank Daswani
Mayank is a senior research engineer working on machine learning for healthcare. His most recent work has focused on mobile sensing - predicting cardiovascular risk from readily available smartphone signals. At Google, he previously worked on machine learning for electronic health records, and on AI-enabled mammography. He graduated with a PhD in Reinforcement Learning from the Australian National University in 2016.
Research Areas
Authored Publications
Sort By
Predicting Cardiovascular Disease Risk using Photoplethysmography and Deep Learning
Sebastien Baur
Christina Chen
Sujay Kakarmath
Mariam Jabara
Babak Behsaz
Shravya Shetty
Goodarz Danaei
Diego Ardila
PLOS Glob Public Health, 4(6)(2024), e0003204
Preview abstract
Cardiovascular diseases (CVDs) are responsible for a large proportion of premature deaths in low- and middle-income countries. Early CVD detection and intervention is critical in these populations, yet many existing CVD risk scores require a physical examination or lab measurements, which can be challenging in such health systems due to limited accessibility. We investigated the potential to use photoplethysmography (PPG), a sensing technology available on most smartphones that can potentially enable large-scale screening at low cost, for CVD risk prediction. We developed a deep learning PPG-based CVD risk score (DLS) to predict the probability of having major adverse cardiovascular events (MACE: non-fatal myocardial infarction, stroke, and cardiovascular death) within ten years, given only age, sex, smoking status and PPG as predictors. We compare the DLS with the office-based refit-WHO score, which adopts the shared predictors from WHO and Globorisk scores (age, sex, smoking status, height, weight and systolic blood pressure) but refitted on the UK Biobank (UKB) cohort. All models were trained on a development dataset (141,509 participants) and evaluated on a geographically separate test (54,856 participants) dataset, both from UKB. DLS’s C-statistic (71.1%, 95% CI 69.9–72.4) is non-inferior to office-based refit-WHO score (70.9%, 95% CI 69.7–72.2; non-inferiority margin of 2.5%, p<0.01) in the test dataset. The calibration of the DLS is satisfactory, with a 1.8% mean absolute calibration error. Adding DLS features to the office-based score increases the C-statistic by 1.0% (95% CI 0.6–1.4). DLS predicts ten-year MACE risk comparable with the office-based refit-WHO score. Interpretability analyses suggest that the DLS-extracted features are related to PPG waveform morphology and are independent of heart rate. Our study provides a proof-of-concept and suggests the potential of a PPG-based approach strategies for community-based primary prevention in resource-limited regions.
View details
Enhancing diagnostic accuracy of medical AI systems via selective deferral to clinicians
Dj Dvijotham
Melih Barsbey
Sumedh Ghaisas
Robert Stanforth
Nick Pawlowski
Patricia Strachan
Zahra Ahmed
Yoram Bachrach
Laura Culp
Jan Freyberg
Atilla Kiraly
Timo Kohlberger
Scott Mayer McKinney
Basil Mustafa
Krzysztof Geras
Jan Witowski
Zhi Zhen Qin
Jacob Creswell
Shravya Shetty
Terry Spitz
Taylan Cemgil
Nature Medicine(2023)
Preview abstract
AI systems trained using deep learning have been shown to achieve expert-level identification of diseases in multiple medical imaging settings1,2. While these results are impressive, they don’t accurately reflect the impact of deployment of such systems in a clinical context. Due to the safety-critical nature of this domain and the fact that AI systems are not perfect and can make inaccurate assessments, they are predominantly deployed as assistive tools for clinical experts3. Although clinicians routinely discuss the diagnostic nuances of medical images with each other, weighing human diagnostic confidence against that of an AI system remains a major unsolved barrier to collaborative decision-making4. Furthermore, it has been observed that diagnostic AI models have complementary strengths and weaknesses compared to clinical experts. Yet, complementarity and the assessment of relative confidence between the members of a diagnostic team has remained largely unexploited in how AI systems are currently used in medical settings5.
In this paper, we study the behavior of a team composed of diagnostic AI model(s) and clinician(s) in diagnosing disease. To go beyond the performance level of a standalone AI system, we develop a novel selective deferral algorithm that can learn to decide when to rely on a diagnostic AI model and when to defer to a clinical expert. Using this algorithm, we demonstrate that the composite AI+human system has enhanced accuracy (both sensitivity and specificity) relative to a human-only or an AI-only baseline. We decouple the development of the deferral AI model from training of the underlying diagnostic AI model(s). Development of the deferral AI model only requires i) the predictions of a model(s) on a tuning set of medical images (separate from the diagnostic AI models’ training data), ii) the diagnoses made by clinicians on these images and iii) the ground truth disease labels corresponding to those images.
Our extensive analysis shows that the selective deferral (SD) system exceeds the performance of either clinicians or AI alone in multiple clinical settings: breast and lung cancer screening. For breast cancer screening, double-reading with arbitration (two readers interpreting each mammogram invoking an arbitrator if needed) is a “gold standard” for performance, never previously exceeded using AI6. The SD system exceeds the accuracy of double-reading with arbitration in a large representative UK screening program (25% reduction in false positives despite equivalent true-positive detection and 66% reduction in the requirement for clinicians to read an image), as well as exceeding the performance of a standalone state-of-art AI system (40% reduction in false positives with equivalent detection of true positives). In a large US dataset the SD system exceeds the accuracy of single-reading by board-certified radiologists and a standalone state-of-art AI system (32% reduction in false positives despite equivalent detection of true positives and 55% reduction in the clinician workload required). The SD system further outperforms both clinical experts alone, and AI alone for the detection of lung cancer in low-dose Computed Tomography images from a large national screening study, with 11% reduction in false positives while maintaining sensitivity given 93% reduction in clinician workload required. Furthermore, the SD system allows controllable trade-offs between sensitivity and specificity and can be tuned to target either specificity or sensitivity as desired for a particular clinical application, or a combination of both.
The system generalizes to multiple distribution shifts, retaining superiority to both the AI system alone and human experts alone. We demonstrate that the SD system retains performance gains even on clinicians not present in the training data for the deferral AI. Furthermore, we test the SD system on a new population where the standalone AI system’s performance significantly degrades. We showcase the few-shot adaptation capability of the SD system by demonstrating that the SD system can obtain superiority to both the standalone AI system and the clinician on the new population after being trained on only 40 cases from the new population.
Our comprehensive assessment demonstrates that a selective deferral system could significantly improve clinical outcomes in multiple medical imaging applications, paving the way for higher performance clinical AI systems that can leverage the complementarity between clinical experts and medical AI tools.
View details
COVID-19 Open-Data: a global-scale spatially granular meta-dataset for coronavirus disease
Oscar Wahltinez
Aurora Cheung
Ruth Alcantara
Donny Cheung
Anthony Erlinger
Matt Lee
Pranali Yawalkar
Paula Lê
Ofir Picazo Navarro
Scientific Data(2022)
Preview abstract
This paper introduces the COVID-19 Open Dataset (COD), available at goo.gle/covid-19-open-data. A static copy is of the dataset is also available at https://doi.org/10.6084/m9.figshare.c.5399355. This is a very large “meta-dataset” of COVID-related data, containing epidemiological information, from 22,579 unique locations within 232 different countries and independent territories. For 62 of these countries we have state-level data, and for 23 of these countries we have county-level data. For 15 countries, COD includes cases and deaths stratified by age or sex. COD also contains information on hospitalizations, vaccinations, and other relevant factors such as mobility, non-pharmaceutical interventions and static demographic attributes. Each location is tagged with a unique identifier so that these different types of information can be easily combined. The data is automatically extracted from 121 different authoritative sources, using scalable open source software. This paper describes the format and construction of the dataset, and includes a preliminary statistical analysis of its content, revealing some interesting patterns.
View details
